Gene: GABRP

2568
-
gamma-aminobutyric acid type A receptor pi subunit
protein-coding
5q35.1
Ensembl:ENSG00000094755 MIM:602729 Vega:OTTHUMG00000130443 UniprotKB:O00591
NG_052803.1
PubMed
0   ANCO-SNPs
AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.711e-2 (AD)  8.218e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FAM20A0.737
TNFAIP80.713
KCNE30.706
TFAP2B0.698
BNC20.69
LUM0.68
TMEM710.679
PLCG20.672
EPS8L10.671
GAPT0.667

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASPDH-0.343
MOXD1-0.343
RND1-0.313
BDH1-0.313
ZNF425-0.311
C19orf73-0.31
HHATL-0.309
KLHL26-0.308
DBP-0.307
C16orf46-0.303

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00231TemazepamSmall Molecule846-50-4Approved|InvestigationalTarget
DB00546AdinazolamSmall Molecule37115-32-5ApprovedTarget
DB00683MidazolamSmall Molecule59467-70-8Approved|IllicitTarget
DB00690FlurazepamSmall Molecule17617-23-1Approved|Illicit|InvestigationalTarget
DB00801HalazepamSmall Molecule23092-17-3Approved|Illicit|WithdrawnTarget
DB00829DiazepamSmall Molecule439-14-5Approved|Illicit|InvestigationalTarget
DB00842OxazepamSmall Molecule604-75-1ApprovedTarget
DB00897TriazolamSmall Molecule28911-01-5Approved|InvestigationalTarget
DB00898EthanolSmall Molecule64-17-5ApprovedTarget
DB01215EstazolamSmall Molecule29975-16-4Approved|IllicitTarget
DB01558BromazepamSmall Molecule1812-30-2Approved|Illicit|InvestigationalTarget
DB01559ClotiazepamSmall Molecule33671-46-4Approved|IllicitTarget
DB01567FludiazepamSmall Molecule3900-31-0Approved|IllicitTarget
DB01588PrazepamSmall Molecule2955-38-6Approved|IllicitTarget
DB01589QuazepamSmall Molecule36735-22-5Approved|IllicitTarget
DB01594CinolazepamSmall Molecule75696-02-5ApprovedTarget
DB01595NitrazepamSmall Molecule146-22-5ApprovedTarget
DB00186LorazepamSmall Molecule846-49-1ApprovedTarget
DB00189EthchlorvynolSmall Molecule113-18-8Approved|Illicit|WithdrawnTarget
DB00228EnfluraneSmall Molecule13838-16-9Approved|InvestigationalTarget
DB00231TemazepamSmall Molecule846-50-4Approved|InvestigationalTarget
DB00237ButabarbitalSmall Molecule125-40-6Approved|IllicitTarget
DB00241ButalbitalSmall Molecule77-26-9Approved|IllicitTarget
DB00273TopiramateSmall Molecule97240-79-4ApprovedTarget
DB00292EtomidateSmall Molecule33125-97-2ApprovedTarget
DB00306TalbutalSmall Molecule115-44-6Approved|IllicitTarget
DB00312PentobarbitalSmall Molecule76-74-4Approved|InvestigationalTarget
DB00334OlanzapineSmall Molecule132539-06-1Approved|InvestigationalTarget
DB00349ClobazamSmall Molecule22316-47-8Approved|IllicitTarget
DB00371MeprobamateSmall Molecule57-53-4Approved|IllicitTarget
DB00402EszopicloneSmall Molecule138729-47-2Approved|InvestigationalTarget
DB00404AlprazolamSmall Molecule28981-97-7Approved|Illicit|InvestigationalTarget
DB00463MetharbitalSmall Molecule50-11-3WithdrawnTarget
DB00475ChlordiazepoxideSmall Molecule58-25-3Approved|Illicit|InvestigationalTarget
DB00543AmoxapineSmall Molecule14028-44-5ApprovedTarget
DB00555LamotrigineSmall Molecule84057-84-1Approved|InvestigationalTarget
DB00628ClorazepateSmall Molecule23887-31-2Approved|IllicitTarget
DB00659AcamprosateSmall Molecule77337-76-9Approved|InvestigationalTarget
DB00753IsofluraneSmall Molecule26675-46-7ApprovedTarget
DB00794PrimidoneSmall Molecule125-33-7ApprovedTarget
DB00801HalazepamSmall Molecule23092-17-3Approved|Illicit|WithdrawnTarget
DB00818PropofolSmall Molecule2078-54-8Approved|InvestigationalTarget
DB00829DiazepamSmall Molecule439-14-5Approved|Illicit|InvestigationalTarget
DB00842OxazepamSmall Molecule604-75-1ApprovedTarget
DB00897TriazolamSmall Molecule28911-01-5Approved|InvestigationalTarget
DB01028MethoxyfluraneSmall Molecule76-38-0Approved|InvestigationalTarget
DB01049Ergoloid mesylateSmall Molecule8067-24-1ApprovedTarget
DB01068ClonazepamSmall Molecule1622-61-3Approved|IllicitTarget
DB01107MethyprylonSmall Molecule125-64-4Approved|Illicit|WithdrawnTarget
DB01159HalothaneSmall Molecule151-67-7ApprovedTarget
DB01189DesfluraneSmall Molecule57041-67-5ApprovedTarget
DB01205FlumazenilSmall Molecule78755-81-4ApprovedTarget
DB01215EstazolamSmall Molecule29975-16-4Approved|IllicitTarget
DB01236SevofluraneSmall Molecule28523-86-6ApprovedTarget
DB01437GlutethimideSmall Molecule77-21-4Approved|IllicitTarget
DB01588PrazepamSmall Molecule2955-38-6Approved|IllicitTarget
DB01589QuazepamSmall Molecule36735-22-5Approved|IllicitTarget
DB01708PrasteroneSmall Molecule53-43-0Approved|Investigational|NutraceuticalTarget
DB01956TaurineSmall Molecule107-35-7Approved|NutraceuticalTarget
DB09118StiripentolSmall Molecule49763-96-4ApprovedTarget
DB11582ThiocolchicosideSmall Molecule602-41-5Approved|InvestigationalTarget
DB11901ApalutamideSmall Molecule956104-40-8Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of GABRP mRNA"27291303
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of GABRP gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of GABRP mRNA16483693
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of GABRP mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to GABRP promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GABRP mRNA22228805
D004958EstradiolEstradiol affects the expression of GABRP mRNA16000229
D004958Estradiol[Estradiol co-treated with Progesterone] results in decreased expression of GABRP mRNA20660070
D004958Estradiol[Estradiol results in increased activity of ESR1 protein] which results in decreased expression of GABRP mRNA22403704
D004958EstradiolEstradiol results in increased expression of GABRP mRNA17010207
C006780bisphenol Abisphenol A affects the expression of GABRP mRNA20170705
C006780bisphenol Abisphenol A results in decreased expression of GABRP mRNA20678512
C006780bisphenol A[bisphenol A results in increased activity of ESR1 protein] which results in decreased expression of GABRP mRNA22403704
C006780bisphenol Abisphenol A results in decreased expression of GABRP mRNA25181051
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GABRP mRNA20938992
D016572CyclosporineCyclosporine results in decreased expression of GABRP mRNA19770486
D003561CytarabineCytarabine results in increased expression of GABRP mRNA21198554
D003634DDT[DDT results in increased activity of ESR1 protein] which results in decreased expression of GABRP mRNA22403704
D003703DemecolcineDemecolcine results in increased expression of GABRP mRNA23649840
C016366dibenzothiophenedibenzothiophene results in decreased expression of GABRP mRNA23656968
D004041Dietary FatsDietary Fats results in increased expression of GABRP mRNA25016146
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of GABRP mRNA17010207
D002117CalcitriolCalcitriol results in increased expression of GABRP mRNA26485663
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of GABRP mRNA20170705
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of GABRP mRNA18936297
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of GABRP mRNA20170705
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of GABRP mRNA17351261
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of GABRP mRNA17557909
D018120FinasterideFinasteride results in decreased expression of GABRP protein27750143
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GABRP mRNA20938992
D005557FormaldehydeFormaldehyde results in increased expression of GABRP mRNA23649840
C039281furanfuran results in increased methylation of GABRP gene22079235
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of GABRP mRNA26752646
C042720mercuric bromidemercuric bromide results in increased expression of GABRP mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GABRP mRNA20938992
D008727MethotrexateMethotrexate affects the expression of GABRP mRNA18502557
D037742Nanotubes, Carbon"Nanotubes, Carbon analog affects the expression of GABRP mRNA"25554681
C031721naphthalenenaphthalene results in decreased expression of GABRP mRNA18757308
D009532NickelNickel results in decreased expression of GABRP mRNA24768652|2558310
C474055octylphenoloctylphenol results in increased expression of GABRP mRNA17010207
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA"25510870
D011374Progesterone[Estradiol co-treated with Progesterone] results in decreased expression of GABRP mRNA20660070
D011374ProgesteroneHOXA10 protein affects the reaction [Progesterone affects the localization of GABRP protein]20103740
D011374ProgesteroneHOXA10 protein affects the reaction [Progesterone results in increased expression of GABRP mRNA]20103740
D011374ProgesteroneProgesterone affects the localization of GABRP protein20103740
D011374ProgesteroneProgesterone results in increased expression of GABRP mRNA20103740
D011374ProgesteroneProgesterone results in decreased expression of GABRP mRNA22238285
D011374ProgesteroneProgesterone results in increased expression of GABRP mRNA19690047
C030984pyrenepyrene results in decreased expression of GABRP mRNA23656968
C017947sodium arsenitesodium arsenite results in decreased expression of GABRP mRNA28595984
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to GABRP promoter]19654925
C009495titanium dioxidetitanium dioxide affects the expression of GABRP mRNA17656681|2355797
D014212TretinoinTretinoin results in decreased expression of GABRP mRNA21934132
D014212TretinoinTretinoin results in increased expression of GABRP mRNA16249480|2383079
C012589trichostatin Atrichostatin A results in increased expression of GABRP mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased methylation of GABRP gene29154799
D014635Valproic AcidValproic Acid results in increased expression of GABRP mRNA24383497|2493525
D015032ZincZinc deficiency results in increased expression of GABRP mRNA20857495
C088658zoledronic acidzoledronic acid results in decreased expression of GABRP mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004890GABA-A receptor activityCONTRIBUTES_TOIBA21873635  
GO:0005230extracellular ligand-gated ion channel activityCONTRIBUTES_TOIBA21873635  
GO:0005230extracellular ligand-gated ion channel activity-IEA-  
GO:0005254chloride channel activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007165signal transduction-IBA21873635  
GO:0007165signal transduction-IEA-  
GO:0007268chemical synaptic transmission-IBA21873635  
GO:0034220ion transmembrane transport-IBA21873635  
GO:0042391regulation of membrane potential-IBA21873635  
GO:0050877nervous system process-IBA21873635  
GO:1902476chloride transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0030054cell junction-IEA-  
GO:0034707chloride channel complex-IEA-  
GO:0043005neuron projection-IBA21873635  
GO:0045202synapse-IBA21873635  
GO:0045211postsynaptic membrane-IEA-  
GO:1902711GABA-A receptor complex-IBA21873635  
KEGG ID KEGG Term
hsa04080Neuroactive ligand-receptor interaction
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23857790Genome-wide DNA methylation patterns in discordant sib pairs with alcohol dependence. (2013 Mar)Zhao RAsia Pac Psychiatry